

will be collected and laid on the Table of the Rajya Sabha.

(1) and (g) The Supreme Court in its judgement on 10th April, 1987 has obser-

ved that profiteering in life saving drugs is diabolic and is a menace which has to be fettered and curbed. The judgement is being examined.

Statement

Sl. No.	Name of the company	Name of the bulk drug/formulation
1	M/s. Glaxo Labs. I. Ltd.	Betamethasone and its formulations.
2	M/s. Cynamid India Ltd.	Tetracyclines & formulations and Diethyl Carbamazine formulations.
3	M/s. Hoechst India Ltd.	Baralgin, Pyrolidine Methyl Tetracycline, Pheniramine, Glybenclamide Fraxemid and formulations.
4	M/s. Pfizer Ltd.	Oxytetracycline, PAS and its salts and formulations based thereon.
5	M/s. Merind Ltd.	Dexamethasone and its formulations.

Marketing of essential medicines by drug companies

1508. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that certain companies were found marketing certain essential medicines falling under Category I and II under other categories;

(b) if so, what are the names of those companies along with the name of each product;

(c) whether his Ministry has worked out the prices of those medicines as per correct mark up;

(d) if so, what is the price worked out and price being charged on each product along with percentage increase in each case;

(e) whether his Ministry issued a claim of difference;

(O if so, what is the amount of claim on each product; »

(g) whether his Ministry has worked out interest on that amount;

(h) if so, at what rate and if not, what are the reasons therefor;

(i) whether his Ministry has taken any penal action against those drug companies; and

(j) if so, what are the details thereof and if not, what are the reasons therefor?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAI-CHANDRAR SINGH): (a) No, Sir.

(b) to (j) Do not arise.

Multinational bias of New Drug Policy

1509. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state;

(a) whether it is a fact that the convention of the various sections of drug industry have considered the New Drug Policy as multinational oriented; and

(b) if so, whether there is any proposal to reconsider the New Drug Policy?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAI-CHANDRA SINGH): (a) Most sections of the drug industry have welcomed and commended the recently announced measures for rationalisation quality control and growth of drugs and pharmaceutical industry.

(b) No, Sir.

Profiteering on drugs

1510. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that a drug company has been charging 1366 percent higher o.a a drug than the Government fixed price since last six years as reported in the Times of India' editorial of 20th April, 1987.

(b) if* so, what is the name of the company alongwith the name of the drug;

(c) names of other drugs and formulations on which higher prices have been charged p.longwith percentage in each case;

(d) what was the year-wise production of each drug during the last three years ending 31st March, 1987; and

(e) names of the formulations based on each of these drugs alongwith the prices fixed and charged on each as well as sales turnover of each during the last three years, yearwise and percentage increase in each case?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAI-CHANDRA SINGH): (a) and (b) Yes, Sir. M/s. Hoechst (India) Limited is charging a price of Rs. 24,725/kg. against the price of Rs. 1,81020/kg. fixed by the Government for bulk drug Baralgan Ketone due to stay orders granted by the Delhi High Court.

(c)- to (e) To the extent information is available names of the companies who are charging their own prices due to stay orders by various High Courts alongwith the names of bulk drugs/formulations concerned are given in the attached Statement (*See below*). Details of production are not available. Sales turnover of formulations is not monitored. The details of prices fixed by the Government and those being charged by the companies will be collected and laid on the Table of the Rajya Sabha.

Statement

Sl. No.	Name of the Company	Name of the Bulk Drug/Formulation
1	2	3
I. Delhi High Court :		
1.	M/s. Glindia (formerly known as) M/s. Glaxo Labs. Ltd.	Betamethasone and its formulations.
II. Supreme Court of India :		
1.	M/s. Geoffrey Manners	Benzathine Penicilline and its formulations.
2.	M/s. Pfizer Ltd.	Oxytetracycline, PAS and its salts and formulations based thereon.